PA5-29287 targets c-Abl in IF, IHC (P), and WB applications and shows reactivity with Human samples.
The PA5-29287 immunogen is recombinant protein fragment corresponding to a region within amino acids 905 and 1089 of Human c-Abl.
Store product as a concentrated solution. Centrifuge briefly prior to opening the vial. For short-term storage (1-2 weeks), product can be stored at 4°C. For long-term storage, aliquot and store product at -20° C or below, avioiding multiple freeze-thaw cycles.
c-Abl (Abelson murine leukemia viral oncogene homolog 1, ABL1) is a 140 kDa proto-oncogene member of the Src family of non-receptor tyrosine kinases. c-Abl has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns c-Abl into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR and c-Abl genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for c-Abl. In chronic myelogenous leukemia and a subset of acute lymphoblastic leukemias, the c-Abl proto oncogene undergoes a (9;22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) As the result of the fusion of c-Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase. The c-Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The c-Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. c-Abl localizes to dynamic actin structures, and phosphorylates CRK and CRKL, DOK1, and other proteins controlling cytoskeleton dynamics. c-ABL potentially regulates DNA repair by activating the proapoptotic pathway when the DNA damage is too severe to be repaired.
⚠WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; ABL; bcr/abl; bcr/c-abl oncogene protein; c-ABL; c-abl oncogene 1; c-abl oncogene 1, receptor tyrosine kinase; JTK7; p150; Proto-oncogene c-Abl; proto-oncogene tyrosine-protein kinase ABL1; receptor tyrosine kinase; Tyrosine-protein kinase ABL1; v-abl; v-abl Abelson murine leukemia viral oncogene homolog 1
Gene Aliases: ABL; ABL1; bcr/abl; c-ABL; c-ABL1; JTK7; p150; v-abl
UniProt ID: (Human) P00519
Entrez Gene ID: (Human) 25